A detailed history allows doctors to determine whether the presenting symptoms are due to an<unk> n or another source. Diagnostic tests such as conjunctival scrapings to look for eosinophils are helpful in determining the cause of the<unk> c response. Antihistamines, mast cell stabilizers or dual activity drugs are safe and usually effective. Corticosteroids are reserved for more severe cases of inflammation, and their use should be monitored by an optometrist due to possible side-effects. When an<unk> n is identified, the person should avoid the<unk> n as much as possible. Non-pharmacological methods If the<unk> n is encountered and the symptoms are mild, a cold compress or artificial tears can be used to provide relief. Mast cell stabilizers Mast cell stabilizers can help people with<unk> c conjunctivitis. They tend to have delayed results, but they have fewer side-effects than the other treatments and last much longer than those of antihistamines. Some people are given an antihistamine at the same time so that there is some relief of symptoms before the mast cell stabilizers becomes effective. Doctors commonly prescribe lodoxamide and nedocromil as mast cell stabilizers, which come as eye drops. A mast cell stabilizer is a class of non-steroid controller medicine that reduces the release of inflammation-causing chemicals from mast cells. They block a calcium channel essential for mast cell degranulation, stabilizing the cell, thus preventing the release of histamine. Decongestants may also be prescribed. Another common mast cell stabilizer that is used for treating<unk> c conjunctivitis is sodium cromoglicate. Antihistamines Antihistamines such as diphenhydramine and chlorpheniramine are commonly used as treatment. People treated with H1 antihistamines exhibit reduced production of histamine and leukotrienes as well as downregulation of adhesion molecule expression on the vasculature which in turn attenuates<unk> c symptoms by 40–50%. Dual Activity Agents Dual-action medications are both mast cell stabilizers and antihistamines. They are the most common prescribed class of topical anti<unk>  agent. Olopatadine (Patanol, Pazeo) and ketotifen fumarate (Alaway or Zaditor) are both commonly prescribed. Ketotifen is available without a prescription in some countries. Corticosteroids Ester based “soft” steroids such as loteprednol (Alrex) are typically sufficient to calm inflammation due to<unk> es, and carry a much lower risk of adverse reactions than amide based steroids. A systematic review of 30 trials, with 17 different treatment comparisons found that all topical antihistamines and mast cell stabilizers included for comparison were effective in reducing symptoms of seasonal<unk> c conjunctivitis. There was not enough evidence to determine differences in long-term efficacy among the treatments. Many of the eye drops can cause burning and stinging, and have side-effects. Proper eye hygiene can improve symptoms, especially with contact lenses. Avoiding precipitants, such as pollen or mold can be preventative. Immunotherapy<unk> n immunotherapy (AIT) treatment involves administering doses of<unk> ns to accustom the body to substances that are generally harmless (pollen, house dust mites), thereby inducing specific long-term tolerance.<unk>  immunotherapy can be administered orally (as sublingual tablets or sublingual drops), or by injections under the skin (subcutaneous). Discovered by Leonard Noon and John Freeman in 1911,<unk>  immunotherapy represents the only causative treatment for respiratory<unk> es. Experimental research has targeted adhesion molecules known as selectins on epithelial cells. These molecules initiate the early capturing and margination of leukocytes from circulation. Selectin antagonists have been examined in preclinical studies, including cutaneous inflammation,<unk>  and ischemia-reperfusion injury. There are four classes of selectin blocking agents: (i) carbohydrate based inhibitors targeting all P-, E-, and L-selectins, (ii) antihuman selectin antibodies, (iii) a recombinant truncated form of PSGL-1 immunoglobulin fusion protein, and (iv) small-molecule inhibitors of selectins. Most selectin blockers have failed phase II/III clinical trials, or the studies were ceased due to their unfavorable pharmacokinetics or prohibitive cost. Sphingolipids, present in yeast like Saccharomyces cerevisiae and plants, have also shown mitigative effects in animal models of gene knockout mice.
symptom of Allergy
symptom of Influenza
symptom of Sinusitis
symptom of Dermatitis
symptom of Arthritis
symptom of Pneumonia
symptom of Croup
symptom of Acne